Evidence map›Paper›PMID 35693995›Full record

ArticleDiabetology international2022

Advanced proliferative diabetic retinopathy and macular edema in acromegaly: a case report and literature review.

Akiko Yuno, Akemi Ikota, Shigeki Koizumi, Yasuo Mashio, Hiroko Imaizumi, Yutaka Sawamura, Akira Shimatsu

Open access · greenAbstract readCase Reports
In one paragraph

Article in Diabetology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Akiko YunoDepartment of Endocrinology and Metabolism, Kin-Ikyo Chuo Hospital, 9-1 Higashi Naebo 5-jo 1-chome, Higashi-ku, Sapporo, Hokkaido 007-8505 Japan.ORCID 0000-0002-5959-6035
Akemi IkotaDepartment of Endocrinology and Metabolism, Kin-Ikyo Chuo Hospital, 9-1 Higashi Naebo 5-jo 1-chome, Higashi-ku, Sapporo, Hokkaido 007-8505 Japan.
Shigeki KoizumiDepartment of Endocrinology and Metabolism, Kin-Ikyo Chuo Hospital, 9-1 Higashi Naebo 5-jo 1-chome, Higashi-ku, Sapporo, Hokkaido 007-8505 Japan.
Yasuo MashioDepartment of Endocrinology and Metabolism, Kin-Ikyo Chuo Hospital, 9-1 Higashi Naebo 5-jo 1-chome, Higashi-ku, Sapporo, Hokkaido 007-8505 Japan.
Hiroko ImaizumiDepartment of Ophthalmology, Sapporo City General Hospital, Sapporo, 060-8604 Japan.
Yutaka SawamuraSawamura Neurosurgery Clinic, Sapporo, 060-0807 Japan.
Akira ShimatsuAdvanced Medical Care Center, Omi Medical Center, Kusatsu, 525-8585 Japan.
Kin-ikyo Chuo Hospital · JPIsuzu Advanced Engineering Center (Japan) · JPSapporo Azabu Neurosurgical Hospital · JPSapporo City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the multimodal management of a patient with proliferative diabetic retinopathy and diabetic macular edema associated with active acromegaly. A 61-year-old Japanese female who had had type 2 diabetic mellitus for > 10 years complained of deteriorated eyesight. She had distinct acromegalic features, and her visual acuity was 0.05 (right) and 0.4 (left) because of sub-capsular cataracts and proliferative diabetic retinopathy with macular edema. Anti-vascular endothelial growth factor treatments, cataract surgeries and retinal direct laser photocoagulation were performed together with gradual glycemic control with basal insulin to prevent worsening of the visual impairment. She was given an injection of a long-acting somatostatin analog (octreotide LAR) and began taking three bolus mealtime insulin shots with basal insulin beginning 1 month before undergoing a trans-sphenoidal adenomectomy. After this successful surgery, her blood glucose levels immediately decreased, and the rapid-acting insulin at mealtimes was discontinued with the observation of normal growth hormone and insulin-like growth factor (IGF)-1 levels, suggesting that her acromegaly was in remission. Her visual acuity improved without a worsening of diabetic retinopathy. Since the increased IGF-1 production in systemic circulation and local vitreous fluids may be one of the aggravating factors for diabetic retinopathy, our patient's acromegaly complicated with severe retinopathy presented an opportunity for multimodal management in close collaboration with an ophthalmologist, neurosurgeon, and endocrinologist. Our literature review revealed that the estimated prevalence of diabetic retinopathy in cases of acromegaly associated with diabetes mellitus is 12.5-42.9%.

Indexed as

AcromegalyGrowth hormoneInsulin-like growth factor 1Proliferative diabetic retinopathyVascular endothelial growth factor

Identifiers

PMID35693995
PMCPMC9174379
OpenAlexW4210490460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.